Journal article
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
Abstract
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA.
METHODS: We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with …
Authors
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y
Journal
New England Journal of Medicine, Vol. 390, No. 10, pp. 911–921
Publisher
Massachusetts Medical Society
Publication Date
March 7, 2024
DOI
10.1056/nejmoa2311155
ISSN
0028-4793